Publications by authors named "Alyssa Kanegai"
Although chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, many patients relapse and therefore strategies to improve antitumor immunity are needed. We previously designed a novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high response rates but relapse was common. Interleukin-15 (IL15) induces proliferation of diverse immune cells and can augment lymphocyte trafficking.
View Article and Find Full Text PDFArticle Synopsis
- A study assessed the immune responses to COVID-19 vaccination in 126 lymphoma patients, finding that only 55% developed blocking antibodies compared to 100% of healthy controls.
- Time since the last anti-CD20 treatment significantly affected vaccine response, with patients treated within 6 months prior to vaccination showing no blocking antibodies.
- The findings suggest that vaccinating lymphoma patients before starting anti-CD20 treatment may help maintain effective antibody responses during ongoing treatment.